Biotech Movers: Regeneron Pops, 3 Flop

Here’s a look at recent major developments and share moves in biotech stocks:

Regeneron Pharmaceuticals (NASDAQ:REGN): Regeneron — the company behind macular degeneration treatment Eylea — popped 11% on a pair of positive headlines last Friday. The company and partner Sanofi (NYSE:SNY) got the support of EU regulators for Zaltrap, a drug meant to be used alongside chemotherapy for patients with colorectal cancer. Regeneron also announced a $70 million expansion of its East Greenbush, N.Y., facilities that would include 65,000 square feet of new space and the addition of 300 new jobs.

Consolidation Provides Good Entry Point for Top Biotech

Dynavax Technologies (NASDAQ:DVAX): Dynavax shares were sliced nearly in half Friday after a huge setback concerning its adult hepatitis B vaccine, Heplisav. An FDA advisory committee on Wednesday said two doses of Heplisav were as effective as three doses of GlaxoSmothKline’s (NYSE:GSK) Engerix-B vaccine. However, on Friday the panel voted 8-5 against the vaccine, saying, “the ability to reliably evaluate uncommon specific autoimmune events is limited due to the size of the study”; the vote sends DVAX back to the drawing board. DVAX finished Friday down 47.3%.

Navidea Biopharmaceuticals (AMEX:NAVB): NAVD slid lower this week after the FDA accepted its New Drug Application resubmission for Lymphoseek but set a six-month target for possible approval instead of an expected two-month approval. The FDA still needs to inspect the facilities of the third-party manufacturer of Lypmphoseek, a radiopharmaceutical agent used for lymph node imaging. NAVB shares fell 16% by the end of last week.

AspenBio Pharma (NASDAQ:APPY): AspenBio — the developer of appendicitis test AppyScore — watched its stock fall Thursday after the company announced a secondary offering. AspenBio will offer 1,476,000 shares at a price of $2.10 for an expected $3.1 million in proceeds, in a deal expected to close Nov. 20. The company currently has 7.72 million outstanding shares. The underwriters also will have a 45-day option to buy up to an additional 221,400 shares to cover over-allotments. APPY finished the week down 16%.

Clovis Oncology (NASDAQ:CLVS): Clovis Oncology dropped to all-time lows last week after its pancreatic cancer treatment proved no more effective than gemcitabine, branded by Eli Lilly’s (NYSE:LLY) as Gemzar. Clovis said Monday it was suspending the development of its drug, CO-101, designed to treat cancer resistant to gemcitabine. CLVS shares finished the week down nearly 46%.

Kyle Woodley is the Assistant Editor of InvestorPlace.com. As of this writing, he did not hold a position in any of the aforementioned securities. Follow him on Twitter at @IPKyleWoodley.